Danaher Co. (NYSE:DHR) Shares Sold by Midland Wealth Advisors LLC

Midland Wealth Advisors LLC decreased its holdings in Danaher Co. (NYSE:DHR) by 16.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,458 shares of the conglomerate’s stock after selling 686 shares during the quarter. Midland Wealth Advisors LLC’s holdings in Danaher were worth $864,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in DHR. Cape Investment Advisory Inc. acquired a new position in Danaher in the fourth quarter worth approximately $25,000. Tsfg LLC grew its position in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the second quarter worth approximately $25,000. nVerses Capital LLC acquired a new position in Danaher in the second quarter worth approximately $25,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Danaher in the first quarter worth approximately $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,659 shares of company stock valued at $11,042,433. Insiders own 11.10% of the company’s stock.

Danaher Stock Down 1.0 %

Shares of DHR stock traded down $2.68 on Tuesday, hitting $266.63. The company’s stock had a trading volume of 456,140 shares, compared to its average volume of 2,789,116. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The firm’s fifty day moving average price is $260.30 and its 200-day moving average price is $255.39. The stock has a market capitalization of $192.56 billion, a price-to-earnings ratio of 45.65, a P/E/G ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the business earned $2.05 EPS. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. Research analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Leerink Partners raised their price objective on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group raised their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Barclays raised their price objective on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. Finally, Robert W. Baird raised their price objective on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.